Global next generation cancer diagnostics market is anticipated to
reach USD 20.25 billion by 2022 growing at an estimated CAGR of 32.0% from 2015
to 2022, according to a new report by Grand View Research Incorporated. Rising
incidence of oncology diseases is anticipated to drive the demand for next
generation cancer diagnostic tests that are expected to enhance early diagnosis
and efficient prognosis of various forms of cancers is a factor expected to
positively influence sector growth over the forecast period.
Cancer diagnostics industry is estimated to witness
lucrative growth over the forecast period majorly due to rising number of
technologically advanced products in the field of companion diagnostics,
providing more precise testing results combined with therapeutic monitoring
early diagnosis of cancer. Moreover, there is a significant shift observed from
traditional laboratory testing to rapid point of care testing, which fuels
growth in the market owing to expected commercialization of technologically
advanced range of products including diagnostic kits, instruments, and
reagents.
Furthermore, supportive government initiatives in order to
increase the number of research projects with respect to oncology and
preventative diagnosis is expected to be attributive for growth in this sector
overthe coming years. Additionally, application of tumor diagnostics in
epigenetic analysis and CTC enumeration for monitoring tumorigenesis is
expected to support projected growth over the forecast period.
Request to Sample
of This Report @ http://www.grandviewresearch.com/industry-analysis/next-generation-cancer-diagnostics-market
Further key findings from the report suggest:
- RT-PCR & multiplexing accounted for the largest share of the market in 2014 with respect to technologies because of the presence of a wide product portfolio that caters to a number of applications in oncology R&D.
- Next generation sequencing solutions for use in cancer diagnostics are expected to witness lucrative growth in revenue over the forecast period owing to the considerable number of advantages the technology offers over its counterpart segment i.e. microarrays. Introduction of novel sequencing platforms and growth oriented initiatives taken by major market participants are other key factors expected to fuel segment growth.
- In January 2016, Illumina launched its MiniSeq system for the sequencing, which provides complete sequencing solution in order to obtain quicker results because of onboard data analysis for numerous assays and workflow with easy-to-use library-to-results. Such strategic initiatives taken by major market entities are also expected to drive this segment further over the forecast period.
- Development and expected commercialization of a number of companion diagnostics is a key factor attributive of anticipated substantial growth in demand and progress of the segment over the next seven years owing to rising sector penetration in this segment for use with therapeutics and novel pharmaceuticals as adjunct in monitoring tumor eradication.
- Dominant industry participants to produce non-small cell lung cancer diagnostic tests anticipate lung cancer to witness substantial growth in market demand because of product development operations carried out.
- Application of oncology diagnostics in biomarker discovery by transcription regulation is expected to drive industry with potential growth avenues as it subsequently proves helpful in drug designing and identification of novel targets for tumor eradication.
- North America held the largest share with respect to revenue generation in 2014 due to simultaneous development of next generation sequencing, personalized medicine and companion diagnostics in the region. Furthermore, high R&D investment as well as availability of technologically advanced healthcare research framework, is expected to serve as a critical factor for the North American region to register considerable growth over the forecast period.
- Presence of significant developments by China and Japan for technological integration, and the development of healthcare infrastructure have poised the Asia Pacific oncology diagnostics market to witness lucrative opportunities of growth throughout the forecast period. Moreover, enhancements of clinical development frameworks in these economies to enable clinical research outsourcing as an effect of the availability of target population is a growth rendering driver in this region.
- Key players contributing significantly to the next generation cancer diagnostics market are Novartis AG, Cepheid, Roche Holdings AG, Perkin Elmer Inc., Sysmex Corporation, Abbott Laboratories, Thermo Fisher Scientific Inc., Philips Electronics NV, Agilent Technologies Inc., Illumina Inc., Genomic Health Inc. Qiagen, Johnson & Johnson, Hologic Inc., Myriad Genetics Inc., Almac Group Limited, Opko Health Inc., and GE Healthcare.
- These entities are involved in collaborations with oncology research organizations and clinical research institutes in order to gain access in the oligopolistic market.
To Get Sample Copy of Report visit
@ http://www.grandviewresearch.com/industry-analysis/next-generation-cancer-diagnostics-market/request
About Grand View
Research
Grand View Research, Inc. is a U.S. based market research and
consulting company, registered in the State of California and headquartered in
San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, the company offers market intelligence studies ensuring
relevant and fact-based research across a range of industries including
technology, chemicals, materials, healthcare and energy.
For More Information,
Visit Grand
View Research
Contact:
Sherry James
Corporate Sales Specialist, U.S.A.
Grand View Research, Inc.
United States
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email:
sales@grandviewresearch.com
No comments:
Post a Comment